Question 1

How does EquitAI evaluate Chemed Corporation's (CHE) valuation and Stock DNA?

Accepted Answer

Chemed Corporation (CHE) trades at $534.72 with an EquitAI Valuation DNA score of 4/10 and Quality score of 10/10. The company's trailing P/E ratio is 25.5x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does Chemed Corporation (CHE) operate in?

Accepted Answer

Chemed Corporation (CHE) is classified under the Healthcare sector within the Medical - Care Facilities industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Medical - Care Facilities peers and broader Healthcare market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for Chemed Corporation (CHE)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $635.0 for Chemed Corporation (CHE), representing an implied 18.8% upside from its current trading level of $534.72 with an average rating of Buy based on 2 analyst ratings. Individual analyst price targets range from a low of $620.0 to a high of $650.0, with a median forecast of $635.0. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does CHE pay dividends or capital distributions?

Accepted Answer

Chemed Corporation has an indicated annual dividend yield of 0.47%. Dividend stability is factored into its Income DNA pillar alongside free cash flow coverage.

Question 5

Who are Chemed Corporation's (CHE) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include BTSG, CLH, NHC, CTAS. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's CHE analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

CHE - Chemed Corporation Stock Analysis & Valuation

Chemed Corporation

FIT ANALYSIS

Pro EquitAI Research Report

The Bull Case

The Bear Case

Business Engine & Moat
Economic Moat: A company's distinct competitive advantage that protects its market share and profitability from competitors.
Wide

Financial DNA & Smart Money

The Premium Verdict

Unlock the Full AI Analysis

Recent SEC Filings & Insights